Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) Sees Large Growth in Short Interest

Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) was the recipient of a significant increase in short interest in the month of June. As of June 15th, there was short interest totaling 942,551 shares, an increase of 3,584.7% from the May 31st total of 25,580 shares. Currently, 79.8% of the shares of the company are sold short. Based on an average trading volume of 28,446,970 shares, the days-to-cover ratio is currently 0.0 days.

Hedge Funds Weigh In On Regentis Biomaterials

An institutional investor recently bought a new stake in Regentis Biomaterials stock. AIGH Capital Management LLC acquired a new position in Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) during the first quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 300,000 shares of the company’s stock, valued at approximately $916,000. AIGH Capital Management LLC owned 5.79% of Regentis Biomaterials as of its most recent SEC filing.

Analyst Upgrades and Downgrades

Separately, ThinkEquity raised shares of Regentis Biomaterials to a “strong-buy” rating in a report on Monday, March 2nd. One equities research analyst has rated the stock with a Strong Buy rating, According to MarketBeat, the company presently has a consensus rating of “Strong Buy”.

Regentis Biomaterials Price Performance

RGNT traded down $0.05 during trading on Thursday, reaching $4.15. 169,962 shares of the company were exchanged, compared to its average volume of 16,503,722. Regentis Biomaterials has a 52 week low of $1.23 and a 52 week high of $15.50. The business’s 50 day moving average price is $2.79.

About Regentis Biomaterials

Regentis Biomaterials Ltd. is a regenerative medicine company dedicated to developing tissue repair solutions which seek to restore the health. Regentis Biomaterials Ltd. is based in Herzliya, Israel.